Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-013991
Filing Date
2023-08-08
Accepted
2023-08-08 17:20:41
Documents
78
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q eqrx-20230630x10q.htm   iXBRL 10-Q 1895728
2 EX-10.1 eqrx-20230630xex10d1.htm EX-10.1 42738
3 EX-31.1 eqrx-20230630xex31d1.htm EX-31.1 18569
4 EX-32.1 eqrx-20230630xex32d1.htm EX-32.1 9594
  Complete submission text file 0001558370-23-013991.txt   8584279

Data Files

Seq Description Document Type Size
5 EX-101.SCH eqrx-20230630.xsd EX-101.SCH 52355
6 EX-101.CAL eqrx-20230630_cal.xml EX-101.CAL 46480
7 EX-101.DEF eqrx-20230630_def.xml EX-101.DEF 248476
8 EX-101.LAB eqrx-20230630_lab.xml EX-101.LAB 469554
9 EX-101.PRE eqrx-20230630_pre.xml EX-101.PRE 405180
72 EXTRACTED XBRL INSTANCE DOCUMENT eqrx-20230630x10q_htm.xml XML 1677122
Mailing Address 50 HAMPSHIRE STREET CAMBRIDGE MA 02139
Business Address 50 HAMPSHIRE STREET CAMBRIDGE MA 02139 (617) 315-2255
EQRx, Inc. (Filer) CIK: 0001843762 (see all company filings)

EIN.: 861691173 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40312 | Film No.: 231152588
SIC: 2834 Pharmaceutical Preparations